AcuraStem is a fast growing startup company that was formed in 2016 to create an innovative precision medicine platform. We are a team of PhDs, professors, tech entrepreneurs, and successful drug company veterans employing the latest scientific breakthroughs to address one of the most challenging, but we believe tractable, health problems of our time - Amyotrophic Lateral Sclerosis (ALS). We are developing the best-in-class technology platform which consists of complex cellular models from ALS patient cells, and sophisticated assays which permit our scientists to model patient tissues in the laboratory. Using this advanced technology, we can evaluate the progression of disease and test existing FDA approved therapeutics or combinations of therapeutic approaches to find the most efficacious treatments to slow disease progression. AcuraStem has leveraged this platform to identify a novel target and preclinical lead candidate which we are advancing to the clinic. AcuraStem also provides aAcuraStem is a fast growing startup company that was formed in 2016 to create an innovative precision medicine platform. We are a team of PhDs, professors, tech entrepreneurs, and successful drug company veterans employing the latest scientific breakthroughs to address one of the most challenging, but we believe tractable, health problems of our time -Amyotrophic Lateral Sclerosis (ALS). We are developing the best-in-class technology platform which consists of complex cellular models from ALS patient cells, and sophisticated assays which permit our scientists to model patient tissues in the laboratory. Using this advanced technology, we can evaluate the progression of disease and test existing FDA approved therapeutics or combinations of therapeutic approaches to find the most efficacious treatments to slow disease progression. AcuraStem has leveraged this platform to identify a novel target and preclinical lead candidate which we are advancing to the clinic. AcuraStem also provides access to this technology platform to commercial and academic partners so that they can evaluate their therapeutic candidates under development.

We are a new biotech start-up based in Johnson & Johnson Innovation Center (JLABS), South San Francisco.  We are developing proprietary biologics/ antibodies to harness the power of the immune system to treat and cure cancer and focus on the most powerful biological mechanisms that we believe drive disease pathophysiology. We are seeking a talented intern with a strong background in cellular and molecular immunology and cancer biology to join our therapeutic antibody discovery team. This position will lead an immuno-oncology target discovery project towards clinical candidate nomination. You will be responsible for all aspects of the project from high-level design to assay development and optimization, hybridoma screening and characterization, lead candidate identification, and pre-clinical animal efficacy studies.  Your work will be a key component of Apeximmune’s strategic goals.

Artificial Intelligence for Senior Care

AiCare empowers the elders through smart, safe, and secure environment. Our machine learning analytics, IoT infrastructure, and wearable sensor personalizes the care for each individual. Real-time tracking, intelligent detection and timely prevention promotes healthy and independent senior life.

AbVision Inc. (AVI), previously the Drug Discovery Group of BioVision Inc., is a privately held biopharmaceutical company headquartered in the San Francisco Bay Area. AVI’s most advanced drug discovery efforts aim to develop pipelines of cancer and infectious disease therapeutics that harness the natural power of the immune system to bring first-in-class and best-in-class drugs to the world.AVI asks the question: How can we utilize AVI’s antibody discoveries to facilitate the success in therapies? Frequently, the obstacles lie in the lack of enough sufficient antibody diversity for lead selection. AVI is ready with solutions that are based on our revolutionary approach to creating a diverse array of antibodies. With AVI’s proprietary antibody discovery platform, we are one of leading biopharmaceutical companies to have generated therapeutic and diagnostic antibodies from variety of conventional animals. AVI also pioneered the use of high-throughput reporter cell systems for functio

Amgen is one of the world's largest biotechnology company and is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California.

BioLegend develops world-class, cutting-edge antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, CA. Our mission is to accelerate research and discovery by providing the highest quality products at an outstanding value, along with superior customer service and technical support. Our product expertise covers a diverse set of research areas including Immunology, Neuroscience, Cancer, Stem cells, and Cell Biology. BioLegend's reagents are supported by superior customer service and a quality management system that is certified for ISO 13485:2016. Our aggressive product development program, through technology licensing, collaborations, and internal hybridoma development, produces strategic reagents for use in a variety of applications including: Flow cytometry and mass cytometry, ELISA, ELISPOT, Immunoprecipitation, ChIP, Western blotting, Immunofluorescence microscopy, Immunohistochemistry, In vitro or in vivo functional assays, and Quantitative Multiplexing.

Founded in 2013, Chirp Microsystems, Inc., A TDK Group Company, designs, develops, and manufactures a line of extremely low power, ultrasonic 3D-sensing solutions for consumer electronics, smart homes, industrial automation, and much more.

Fortemedia, Inc., headquartered in the US Silicon Valley and with global operations and offices in Asia, focuses on developing high quality solutions and semiconductor products that provide advanced voice processing technologies to enhance human-to-human and human-to-machine voice communication efficiencies.

IGE Pharmaceuticals is conducting R&D in FDA drug delivery to the US and international market. We will provide comprehensive and intensive training to Creative Star Scientist(s) to deepen their skill in FDA drug discovery. The R&D pipeline drugs include: in proprietary biologics for anti-inflammatory and anti-fibrotic vaccines, anti-cancer vaccines, immunotherapy for allergy and autoimmune diseases for FDA-CBER. The small molecule pipeline drugs include using RNA interference to treat allergic inflammation and fibrotic diseases for FDA-CDER. The training Programs are for talented, career-minded individuals interested in areas of drug discovery for allergy, autoimmune diseases, metabolic syndromes, insulin resistance and cancers. The knowledge bases provided in the training Programs include cytotoxic T lymphocytes, immunoregulatory T cells, dendritic cells, epithelial cells, NK cells, innate lymphoid cells, and monoclonal antibodies. The technology platforms provided in the Programs include the proprietary mRNA/ribosome display platform, protein scaffolds, molecular evolution to suit 3-dimensional conformationally constrained peptide and/or protein based vaccine discovery.

Ideas Lab enables data-driven insights from the way people move, perform and play. We leverage a suite of technologies including Artificial Intelligence, Machine Learning, Computer Vision, sensor fusion, and human pose estimation, to generate prescriptive analytics. Because our technologies lie squarely at the intersection of human movement and data analytics, there are multiple use cases where our solution can be transformative; we focus on two core areas, currently: Sports and Healthcare. Our technology includes proprietary algorithms and data models that are domain-specific and driven by both human and artificial intelligence. We are entrepreneurs, designers, technologists and dreamers and, together, represent deep expertise in the core technologies, domains and business models in which we operate.

In 1992, surgery faced inevitable changes, shifting from the industrial era to the computer era. In this context, Prof. Jacques Marescaux came up with the idea to create an original research and training center. In 1994, IRCAD opened on the grounds of the University Hospital of Strasbourg. Since its creation, IRCAD has gained world renowned fame as a leading research and education institute. In 2001, Professor Marescaux electrified the surgical world with “Operation Lindbergh”. Sitting at a robotic console in New York City, Professor Marescaux dexterously removed the diseased gallbladder of a patient in Strasbourg, France – the perfect blending of information technology and surgery. Just as Lindbergh’s solo flight across the Atlantic revolutionized our thinking, so too did this worldwide first, proving that distances were no longer an obstacle in surgery.

IRCAD’s research orientation has always been directed towards the development of less invasive surgical techniques. The development of concepts and instruments enabled the IRCAD team to carry out the first fully natural orifice transluminal endoscopy surgical (NOTES) procedure in April 2007. The parallel development of a training structure was the logical extension of the groundbreaking work at IRCAD. Every year, 5,700 surgeons from all over the world are trained by a team of 800 international experts. The IRCAD made it possible for surgeons from the entire world to obtain high-level skills, and as a result, the Institute maintained its position as an ambassador of French excellence.

IRCAD’s international success led to the construction of a twin institute in Taiwan (Asia IRCAD – AITS) in 2008, under the guidance of M. H. Huang, President of Show Chwan Memorial Hospital. This mirror institute was created in Taiwan because of the sheer necessity of creating such a network in Asia, using its European counterpart as a structural blueprint. A few years later, in 2011, IRCAD América Latina was inaugurated in the State of Sao Paulo, Brazil. It embodies the fruitful partnership with Henrique Prata and Hospital de Cancer de Barretos. A third mirror institute has opened in June 2017 in Rio de Janeiro, Brazil thanks to the partnership with United Health and its former CEO Edson Bueno. A new institute will be inaugurated in 2019 in Rwanda, Africa.

Intel is one of the largest semiconductor chip makers, known for making microprocessors in most PC today. One of the opens is from Intel Labs. Intel Labs, the research arm of Intel Corporation, is inventing tomorrow's technology to make our lives easier, more enjoyable and more productive.  We fuel Intel’s growth and deliver breakthrough technologies that bring the benefits of the ongoing digital revolution to everyone.

IBM is a multinational technology company headquartered in Armonk, New York, United States, with operations in over 170 countries. IBM manufactures and markets computer hardware, middleware, and software, and provides hosting and consulting services in areas ranging from mainframe computers to nanotechnology. IBM is also a major research organization, holding the record for most U.S. patents generated by a business (as of 2018) for 25 consecutive years.

Jasper Display Corp., operations started in 2010, is a leading designer of SLM (Spatial Light Modulators) and has successfully developed and brought to the marketplace several new, very high speed Full HD (FHD) microdisplays and a microdisplay controller, establishing a line of new LCoS products to support color-sequential single-microdisplay operated at FHD resolution and high frame rate. In addition, Jasper Display has the world’s smallest Ultra HD (UHD) microdisplay in the world. Jasper Display’s newest addition, the OCM, will now add an ASIC controller to drive the full line of microdisplays from FHD to UHD microdisplays.

Kneron, a leading provider of edge AI solutions, was founded in 2015 at San Diego, US by Albert Liu who is a leading expert in ASIC design, EDA, deep learning, image processing, and computer vision algorithms. Barely two years old, Kneron already has partners and customers around the world, and has provided customized solutions for home appliances, surveillance, and smart phones to several international companies. Kneron offers innovative edge AI solutions by moving part of the AI computing power from cloud to edge devices, which differentiates itself from traditional cloud-based AI solution providers. Kneron’s edge AI solutions are able to do real-time recognition, inference, and analysis with no need to connect to the cloud. Thus, the solutions are faster, more reliable and secure, while reducing significantly cost and the cloud burden. Kneron’s solutions include ASIC (Application-specific integrated circuit) chip for AI, Neural Processing Unit (NPU), and its software solution, Reconfigurable Artificial Neural Network, which adopts advanced algorithm to enable quick implementation of different AI applications, including face detection and recognition, body & gesture detection, object detection, and behavior & scene detection.Currently, Kneron has offices in San Diego, Taipei, Zhuhai, and Shenzhen, and its core team members are from world top universities, such as Berkeley and MIT. On November 15, 2017, Kneron announced the completion of series A financing at over ten million US dollars. Alibaba Entrepreneurs Fund and CDIB Capital Group are the lead investors, and Himax Technologies, Inc., Qualcomm, Thundersoft, Sequoia Capital (its sub funds: Cloudatlas), and CY ZONE are co-investors. Kneron will cooperate with its strategic partners to promote the edge AI technologies and speed up the popularity of AI applications. Kneron has earned recognition for its innovative technologies and development potential. Kneron participated in Qualcomm Sequoia Frontier Tech Startup Competition 2017, held by Qualcomm, Sequoia Frontier Tech Startup, and Cyzone jointly, and won the first place in the finals with DEMO GOD Award.

LIGHTEL is an advanced technology company located in Seattle to service the Fiber Optic & Photonics industries worldwide. The new focus is to develop Hi-power (KW) technologies for Fiber Laser applications to serve the Industry 4.0., IMS (IntelligentManufacturing System) and Defense sectors.

LIGHTMED is a medical device and technology company focused on developing, manufacturing and marketing a full spectrum of innovative laser systems for the ophthalmic market. Our product suite includes advanced solutions for cataract, glaucoma, corneal, and retinal diseases. We have been in business since 1997 with our own R&D and manufacturing facility, and now we have meaningful global market share estimated as ~7%. All of our products are backed by an industry leading warranty and guaranteed with proactive routine inspections through our sales and service centers located worldwide.

Lin BioScience, Inc. is a drug development company specializing in innovative therapies for diseases with unmet medical needs. Our diverse and novel pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in oncology, ophthalmology, cardiovascular and metabolic disease.

If you are inspired by the possibilities of science to change lives and you thrive when making brave decisions join us. MedImmune is the worldwide biologics research and development arm of AstraZeneca. Here, you will have the opportunity to make a difference in people’s lives every day. As one of the world’s premier biotechnology companies, our mission is centered on delivering life-changing products that advance world health, and help fight and cure disease.

As a postdoctoral intern in Gaithersburg, MD you will play a pivotal role in channeling our scientific capabilities to make a positive impact on changing patient’s lives. Were constantly pushing the boundaries of science to deliver life-changing medicines to patients, with a passion for discovery and a pipeline to show for it. We are pioneering innovative research and exploring novel pathways across key therapeutic areas including oncology, respiratory, inflammation and autoimmunity, cardiovascular and metabolic disease, and infection and vaccines. And were industry-leading in immunology, protein engineering and translational science.

We offer a unique and strong collaborative network as part of the AstraZeneca family, as together we explore synergies between small and large molecules. MedImmune has a dynamic environment that fosters collaboration and innovation. We attract top minds, and we nurture and build top talent.

Niche Biomedical is a company dedicated to developing novel therapeutic and diagnostic neuromodualtion devices with a mission to drastically improve the quality of human life and to treat chronic diseases/injuries incurable through conventional pharmaceutical drugs.         

NeuVector is the leader in Kubernetes security and delivers the first and only multi-vector container security platform. NeuVector enables the confident deployment of enterprise-wide container strategies, across multi-cloud and on-premise environments. NeuVector delivers east-west container traffic visibility, host security and container inspection in a highly integrated, automated security solution. NeuVector customers include global leaders in financial services, healthcare and publishing, and NeuVector partners with AWS, Docker, Google, IBM, Rancher, Red Hat and others. Founded by industry veterans from Fortinet, VMware, and Trend Micro, NeuVector has developed patent-pending behavioral learning and network inspection for container security.

NVIDIA's invention of the GPU in 1999 sparked the growth of the PC gaming market, redefined modern computer graphics, and revolutionized parallel computing. More recently, GPU deep learning ignited modern AI -he next era of computing - with the GPU acting as the brain of computers, robots, and self-driving cars that can perceive and understand the world.

NanoCellect is a biotechnology company that is leading the sector of cell analysis with its unique product series of tabletop flow cytometer and FACS systems and single cell analysis system.  It produces the most advanced cell analysis products with its patented microfluidics, photonics, electronics, and software technologies.

ONYX Healthcare Inc. (ONYX), founded in 2010, has made its initial public offering (IPO) in biotechnology segment on January 15th, 2016.  The company focuses on designing, manufacturing, and distribution of ONYX branded medical grade computers and custom built medical device solutions for worldwide medical computing industry.

About PfizerGood health is vital to all of us， and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That's why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe， effective and affordable medicines and related health care services to the people who need them.We have a leading portfolio of products and medicines that support wellness and prevention， as well as treatment and cures for diseases across a broad range of therapeutic areas; and we have an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared diseases of our time， like Alzheimer's disease and cancer.To ensure we can continue to deliver on our commitments to the patients， customers and shareholders who rely on us， we are focused on improving the way we do business; on operating with transparency everything we do; and on listening to the views of all of the people involved in health care decisions. Through working in partnership with everyone from patients to health care providers and managed care organizations to world governments and non-governmental organizations, our goal is to ensure that people everywhere have access to innovative treatments and quality health care.  (Pfizer.com)

Pathover specializes in using artificial intelligence and machine learning techniques to optimize same-day logistics.

Paygilant's technology is designed to prevent mobile payments and money transfer fraud (NFC, QR code, P2P, In-app), on the mobile device in the pre- authorization phase. Paygilant’s mobile fraud prevention solution is a combination of smart, independent and compact on-device risk engine and powerful back-end analytics to support it. Paygilant’s SDK carries with it the intelligence required to perform the risk assessment on the device itself, without involving any back-end in the process. Paygilant’s risk assessment process is based on proprietary behavioral maps. These multi-dimensional maps represent the purchasing behavior and the unique Augmented Device Identification of each customer. Paygilant protects the entire journey from onboarding to transacting.

Mission statement of the company
Paygilant’s mission is to deliver a vigilant solution against mobile payments and money transfer fraud. Paygilant autonomous disruptive technology makes contactless payments, eWalllet and online transactions easy and secure, increasing conversion rates and reducing customers friction. Issuers, merchants and payment service providers benefit from a proven reduction in risk and fraud losses, while enhancing the payment experience and cutting over 60% of the associated operational cost.

Efforts at Research & Development (R&D) and innovation are the core values to maintain Surface Bioadvances Inc. at the highest technological level in the global market. These values make us be a true partner to the Pharma, Cosmetic, and Biotechnological companies in the world.In terms of Research, we have received two Phase I STTR awards from National Institutes of Health (NIH) to identify skin probiotic bacteria as well as develop novel drugs, vaccines, probiotics and diagnostics derived from the human skin microbiome. For Development, we are developing various ingredients for foods, cosmetic products, and medicines. These ingredients are mainly isolated from probiotic bacteria and/or their metabolites. The R&D projects at Surface Bioadvances Inc. are managed from the technical side but also from legal and financial point of view. This structure is an integral part of our team being made available for joint developments with our customers.

Taiwania Capital Management Corporation ("Taiwania Capital") founded in 2017, is a Venture Capital firm based in Taiwan and Silicon Valley. We are Taiwan's national investment arm and are backed with government's resources and support. 

The goals of Taiwania Capital are to establish partnership with worldwide companies and to boost Taiwan's economic growth. By partnering with the cutting edge startups, we stimulate innovation in sectors including information and communication technology (ICT), biotech, material, energy, new agriculture, etc.

We connect startups to seasoned entrepreneurs and industry leaders. Taiwania Capital's CEO David Weng has more than 20 years of investment experience in Silicon Valley.  Our mentor group includes entrepreneurs with million-dollar and billion-dollar exits experiences from software and hardware industries. 

Taiwania Capital's name comes from "Taiwania" which is one of the largest tree species in Asia. It was first discovered in Taiwan more than one hundred years ago and named after Taiwan.

The Biomedical Research Institute of Southern California (BRISC) is a non-profit research institute located in San Diego North County, California. BRISC’s scientists conduct basic research to advance our understanding of the fundamental mechanisms of normal biological processes and how those differ in disease states. Our goal is to identify new ways to diagnose, prevent or treat human disease. Our areas of interest include vaccines and infectious disease, diabetes, cancer and asthma.

ThermovisionUSA (aka TVUSA) is developing an eco-system that provides a cyber tele-healthcare service for breast wellness and disease (including cancer) screening. The key component of this eco-system is a microwave sensor that accompanies with the AI/ML/Deep Learning model and classification algorithm for an early detection of breast disease and cancer. The IoT technique, such as front-end and back-end APPs, is another part of development for the eco-system.

Taboola is the leading discovery platform, serving over 450 billion recommendations of articles, blogs, videos, products and apps to over one billion unique users every month on thousands of premium sites and mobile carriers. Publishers, brand marketers, and performance advertisers leverage Taboola to retain users on their sites, monetize their traffic, and distribute organic and sponsored content as well as video to engage high-quality audiences. Partners include: USA TODAY, Huffington Post, MSN, Business Insider, The Independent, Welt, L’Express and The Weather Channel. A global company with local service touchpoints, Taboola is headquartered in New York City with offices in Los Angeles, London, Tel Aviv, New Delhi, Bangkok, Sao Paulo, Mexico City, Berlin, Paris, Beijing, Shanghai, Istanbul, Seoul, Sydney and Tokyo.

Tubis Technology is developing mmWave Phased-Array antenna for Satellite markets (Both ground terminals and satellite) and 5G Cellular phone markets. Major technical areas are mmWave semiconductors for phased-array frontend processing, antenna and IC packaging, and array panel/housing development, testing, and production.

Zymolo Inc. is a Microbiome company located in United States of America (USA). By discovery of fermentation (Zymological) activities of probiotic bacteria, Zymolo Inc., is able to 1) isolate various probiotic bacteria; 2) identify various carbon sources; 3) synthesize therapeutic analogs of fermentation metabolites; and 4) develop the profile of antibodies to microbiome as diagnostic platforms.Mission:Our mission at Zymolo Inc. is to promote the health by rebalancing the dysbiotic human microbiome.